# Current status and future prospects of brain–computer interfaces in the field of neurological disease rehabilitation

**Authors:** Yu Luo, Xiaohu Liu, Miaomiao Yang

PMC · DOI: 10.3389/fresc.2026.1666530 · Frontiers in Rehabilitation Sciences · 2026-02-10

## TL;DR

This paper reviews how brain-computer interfaces (BCIs) can help people with neurological diseases recover, while identifying key challenges and future directions for the technology.

## Contribution

The paper proposes a roadmap for next-generation BCI rehabilitation, including adaptive therapy and individualized cortical simulators.

## Key findings

- BCI technology shows promise for neurological rehabilitation but faces limitations like small sample sizes and protocol heterogeneity.
- The review highlights the applicability of BCI in motor restoration and emerging areas like neuropathic pain.
- A research roadmap suggests integrating adaptive therapy and proprioceptive feedback mechanisms for improved rehabilitation outcomes.

## Abstract

Neurological disorders represent a significant category of diseases that profoundly affect human health, accounting for the second leading cause of global mortality. This group of conditions includes stroke, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), spinal cord injury, Parkinson's disease, and cerebral palsy, among others. These disorders are highly susceptible to sequelae and profoundly impact individuals’ daily lives. In this context, Brain-Computer Interface (BCI) technology has demonstrated considerable potential in the domain of neurorehabilitation, although numerous challenges remain. The manuscript provides a comprehensive review of recent advancements in research and clinical applications, highlighting current limitations and outlining future directions. It elucidates the applicability and constraints of Brain-Computer Interface (BCI) technology across various diseases and patient populations. To facilitate insights across different conditions, comparative tables are presented, aligning BCI strategies with therapeutic targets, outcomes, advantages, limitations, and existing evidence gaps. The scope extends beyond motor restoration to include under-explored domains, such as neuropathic pain, with a focus on real-world translation, including home and community feasibility and the distinction between assistive and rehabilitative applications. The review distills overarching limitations within the field, such as small sample sizes, protocol heterogeneity, and limited longitudinal evidence, while synthesizing the most recent studies. An actionable research and development roadmap is proposed to guide next-generation BCI rehabilitation, incorporating individualized cortical-network simulators, self-architecting decoders, adaptive therapy approaches akin to game seasons, and proprioceptive “write-back” mechanisms via peripheral interfaces. Moreover, the review reveals significant research focal points and critical issues that warrant further investigation in the context of neurological rehabilitation utilizing BCI technology.

## Linked entities

- **Diseases:** stroke (MONDO:0005098), multiple sclerosis (MONDO:0005301), amyotrophic lateral sclerosis (MONDO:0004976), spinal cord injury (MONDO:0043797), Parkinson's disease (MONDO:0005180), cerebral palsy (MONDO:0006497)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}
- **Diseases:** diabetic peripheral neuropathy (MESH:D010523), dementia (MESH:D003704), autonomic dysreflexia (MESH:D020211), sensory hypersensitivity (MESH:D004342), sensory loss (MESH:C580162), corticospinal dysfunction (MESH:D006331), involuntary movement (MESH:D020820), degeneration (MESH:D009410), trigeminal neuralgia (MESH:D014277), NP (MESH:D009437), gait impairment (MESH:D020234), motor control deficits (MESH:D007174), dyskinesia (MESH:D004409), chronic pain (MESH:D059350), depression (MESH:D003866), dopaminergic (MESH:D009422), Brown-Sequard (MESH:D018437), Cognitive impairment (MESH:D003072), disability (MESH:D009069), basal-ganglia/thalamic injury (MESH:D001480), brain and neurological cancers (MESH:D001932), chronic (MESH:D002908), MI (MESH:D000068079), infectious neurological diseases (MESH:D003141), MS (MESH:D009103), frontotemporal dementia (MESH:D057180), allodynia (MESH:D006930), rigidity (MESH:D009127), exercise (MESH:D000092202), brain injuries (MESH:D001930), neurological injury (MESH:D020196), Demyelination (MESH:D003711), ataxia (MESH:D001259), death (MESH:D003643), GMFCS I-II (MESH:D008310), dorsal-root lesions (MESH:D000092142), tremor (MESH:D014202), bradykinesia (MESH:D018476), brain damage (MESH:D001925), perceptual and intellectual deficits (MESH:D010468), Uhthoff's phenomenon (MESH:D009222), Ataxic (MESH:D001039), dysmetria (MESH:D002524), epilepsy (MESH:D004827), hallucinations (MESH:D006212), ALS (MESH:D000690), dysphagia (MESH:D003680), birth defects (MESH:D000014), thrombosis (MESH:D013927), disorders of movement and posture (MESH:D054972), pressure injury (MESH:D003668), hemiparesis (MESH:D010291), AIS (MESH:D013734), co-contraction (MESH:D004370), infections (MESH:D007239), diabetic neuropathy (MESH:D003929), ERD (MESH:D002318), ischemic injury (MESH:D017202), Post (MESH:D000094025), distal dexterity loss (MESH:D049310)
- **Chemicals:** riluzole (MESH:D019782), Dopamine (MESH:D004298), antispastics (-), levodopa (MESH:D007980), edaravone (MESH:D000077553), glutamate (MESH:D018698), dalfampridine (MESH:D015761)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929526/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929526/full.md

## References

334 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929526/full.md

---
Source: https://tomesphere.com/paper/PMC12929526